Market Overview

Ignyta Reports Granting of Inducement Awards

Share:

Ignyta, Inc. (NASDAQ:RXDX), a biotechnology company focused
on precision medicine in oncology, announced today that it has issued
two inducement awards to new non-executive employees.

The awards were made on November 15, 2017, under Ignyta's 2017
Employment Inducement Equity Incentive Award Plan, which was adopted on
August 17, 2017, and provides for the granting of equity awards to new
employees of Ignyta. The inducement awards were not individually
negotiated and consist of options to purchase an aggregate of 65,000
shares of Ignyta common stock and each has a ten-year term. The exercise
price of the options was $15.00, which was the per-share closing price
of Ignyta's common stock on the Nasdaq Capital Market on November 15,
2017. Each option vests over a four-year period, with 25% vesting on the
first anniversary of the date of hire and the remainder vesting in equal
monthly installments over the three years thereafter. The awards were
approved by the independent compensation committee of Ignyta's board of
directors and were granted as inducements material to the new employees
entering into employment with Ignyta in accordance with Nasdaq
Marketplace Rule 5635(c)(4).

About Ignyta, Inc.

Blazing a New Future for Patients with Cancer™

At Ignyta, we work tirelessly on behalf of patients with cancer to offer
potentially life-saving, precisely targeted therapeutics (Rx) guided by
diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter
uncharted territory, illuminating the molecular and immunological
drivers of cancer and quickly advancing treatments to address them. This
approach embraces even those patients with rare cancers, who have the
highest unmet need and who may otherwise not have access to effective
treatment options. With our pipeline of potentially first-in-class or
best-in-class precision medicines, we are pursuing the ultimate goal of
not just shrinking tumors, but eradicating cancer relapse and recurrence
in precisely defined patient populations.

For more information, please visit: www.ignyta.com.

View Comments and Join the Discussion!
 

Partner Center